PEPTIDE CANCER VACCINE MARKET ANALYSIS

Peptide Cancer Vaccine MarketSize and Trends

Peptide cancer vaccines aid to elicit and expand tumor-specific T-cells capable of controlling or eradicating tumor. The vaccine consists of one or more short or long amino acid sequences as tumor antigens, combined with vaccine adjuvant. In the recent past, results of clinical trials performed using peptide cancer vaccine had exhibited negative outcomes. So, researchers in the peptide vaccine have considered this as outdated therapy and declared it as no longer viable for cancer treatment. However, increasing progress in understanding critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has led to re-emergence of this approach for the treatment of malignant disorders.

Furthermore, advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, easy to prepare, and its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to foster growth of the peptide cancer vaccine market in the near future. Therefore, owing to these advantages, manufacturers are focusing on research, to develop peptide cancer vaccines. For instance, in April 2018, Boston Biomedical, Inc., involved in next generation cancer therapeutics, initiated dosing of the first patient in each of two clinical studies to evaluate the results of its affectability by using DSP-7888, an investigational cancer peptide vaccine. 

Market Trends

Furthermore, to cater to increasing demand for vaccines, manufacturers are also involved in mergers and acquisitions and new product launches in the peptide cancer vaccine market. For instance, in May 2018, Merck & Co. invested US$ 125 Million in Moderna Therapeutics. This expansion included partnering on mRNA-5671, Moderna’s mRNA KRAS cancer vaccine, and other shared antigen mRNA cancer vaccines. This vaccine includes an mRNA for four most commonly found KRAS mutations, which according to Moderna will cover most of the mutation that occur in non-small-cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. In November 2017, Moderna launched the Phase I KEYNOTE-603 study of mRNA-4157, an mRNA-based personalized cancer vaccine being developed with Merck & Co., through a US$ 100-million-plus mRNA partnership.

Furthermore, in November 2017, TapImmune Inc., a clinical-stage immune-oncology company with ongoing clinical trials in breast and ovarian cancer, announced that the company has enrolled the final patient in randomized Phase 2 clinical study for its novel T-cell vaccine candidate TPIV200 for the treatment of triple-negative breast cancer (TNBC). More such clinical trials for peptide cancer vaccines are expected to boost growth of the global peptide cancer vaccine market over the forecast period.